FLT3 and acute myeloid leukemia: Regarding R/R AML with FLT3 mutations, inhibitors of mutated FLT3 such as sorafenib alone or in combination with chemotherapy can improve both response rate and long-term survival, so these FLT3 inhibitors nowadays act as a targeted drug for FLT3-mutated AML.